SillaJen and NCI to evaluate Pexa-Vec with PD-L1 and CTLA-4 antibodies

SillaJen Inc. (KOSDAQ:215600) entered into a cooperative research and development agreement (CRADA) with NIH's National Cancer Institute to evaluate the biotech's Pexa-Vec pexastimogene in combination with undisclosed antibodies targeting PD-L1 and cytotoxic T-lymphocyte associated protein 4 (CTLA-4; CTLA4; CD152) in an "early phase clinical trial" to treat advanced colorectal cancer...